RecruitingRecruiting
Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)
NCT07029009 · Children's Hospital Medical Center, Cincinnati
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Investigating Enteroendocrine Dysfunction, Metabolism, and Response to Liraglutide in Patients With Maturity-onset Diabetes of the Young (MODY)
About this study
The objective of this study is to perform a comprehensive metabolic and hormonal evaluation of individuals with Maturity-onset diabetes of the young (MODY) at baseline and then assess response to initiation of liraglutide. Select individuals will be consented for human induced pluripotent stem cell (iPSC) generation to identify the cellular basis of enteroendocrine cell (EEC) dysfunction.
The hypothesis is that heterozygous mutations in MODY-related genes contribute to a range of GI pathologies, including regional disruptions in epithelial identity and disturbances in the function of EECs. Thus, patients with MODY may experience improvement not only in HbA1c and BMI but also in GI symptoms with initiation of GLP-1 receptor agonists. Investigators plan to enroll approximately 50 patients with MODY and obtain baseline metabolic labs and imaging along with enteroendocrine labs before initiating liraglutide and assessing response with repeat labs and imaging. This project will provide further guidance for clinical care and treatment of patients with MODY.
Eligibility criteria
Inclusion Criteria:
* Diagnosis of MODY via genetic testing
* HgbA1c \>6.5%
Exclusion Criteria:
* History of anaphylaxis to GLP-1 receptor agonists
* Already taking GLP-1 receptor agonists
* on medications within the stimulant class
* have had bariatric surgery
* personal or family history of cancer, especially medullary thyroid cancer
* personal history of pancreatitis or pathogenic variants associated with increased risk of pancreatitis
* known active kidney disease
* severe hypoglycemia (glucose \< 50 mg/dL) within 3 months of study enrollment
* HbA1c \> 10.0%
* episode of diabetic ketoacidosis (DKA) in the past 3 months
* are currently pregnant
* BMI \< 18.5 kg/m2 and pediatric patients with BMI \< 5th percentile
Study design
Enrollment target: 50 participants
Allocation: na
Masking: none
Age groups: child, adult, older_adult
Timeline
Starts: 2025-05-08
Estimated completion: 2027-01
Last updated: 2025-12-17
Interventions
Drug: Liraglutide
Primary outcomes
- • Blood sugar control - HbA1C (Baseline and 3 months after study treatment initiation)
- • BMI (baseline, 1 month, 2 months, and final study visit 3 months after study treatment initiation)
Sponsor
Mansa · other
Contacts & investigators
ContactMansa Krishnamurthy, M.D. · contact · mansa.krishnamurthy@cchmc.org · 513-636-4744
InvestigatorMansa Krishnamurthy, M.D. · principal_investigator, Children's Hospital Medical Center, Cincinnati
All locations (1)
Cincinnati Children's Hospital Medical CenterRecruiting
Cincinnati, Ohio, United States